Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMA LORRE : revenue, balance sheet and financial ratios

PHARMA LORRE is a French company founded 2 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in SAINT-ERBLON (35230), this company of category PME shows in 2025 a net income positive of 74 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMA LORRE (SIREN 952875094)
Indicator 2025 2024
Revenue N/C N/C
Net income 73 843 € -45 159 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2025, PHARMA LORRE generates positive net income of 74 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

73 843 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1550%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1549.808%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

6.052%

Solvency indicators evolution
PHARMA LORRE

Sector positioning

Debt ratio
1549.81 2025
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Watch +50 pts over 2 years

In 2025, the debt ratio of PHARMA LORRE (1549.81) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
6.05% 2025
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Average

In 2025, the financial autonomy of PHARMA LORRE (6.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 1538.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

1538.194

Liquidity indicators evolution
PHARMA LORRE

Sector positioning

Liquidity ratio
1538.19 2025
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Good

In 2025, the liquidity ratio of PHARMA LORRE (1538.19) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positioning of PHARMA LORRE in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of PHARMA LORRE is estimated at 765 515 € (range 474 508€ - 1 190 618€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
474k€ 765k€ 1190k€
765 515 € Range: 474 508€ - 1 190 618€
NAF 5 all-time

Valuation method used

Net Income Multiple
73 843 € × 10.4x = 765 516 €
Range: 474 508€ - 1 190 618€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare PHARMA LORRE with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about PHARMA LORRE

What is the revenue of PHARMA LORRE ?

The revenue of PHARMA LORRE is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMA LORRE profitable?

Yes, PHARMA LORRE generated a net profit of 74 k€ in 2025.

Where is the headquarters of PHARMA LORRE ?

The headquarters of PHARMA LORRE is located in SAINT-ERBLON (35230), in the department Ille-et-Vilaine.

Where to find the tax return of PHARMA LORRE ?

The tax return of PHARMA LORRE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMA LORRE operate?

PHARMA LORRE operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.